Immune Design to Present at Upcoming Investor Conferences in September

SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) — Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that the company will present at two upcoming investor conferences in September.

2017 Wells Fargo Securities Healthcare Conference
Thursday, September 7, 2017 at 10:00 a.m. Eastern Time in Boston.

Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Thursday, September 28, 2017 at 10:30 a.m. Eastern Time in New York.

A live webcast of each presentation will be available online from the investor relations page of the company’s corporate website at  After the live webcast, an archive of each presentation will be available on the company website for 30 days.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases.  CMB305 and G100, the primary foci of Immune Design’s ongoing immuno-oncology clinical programs, are products of its two synergistic discovery platforms, ZVex® and GLAAS®.  Immune Design has offices in Seattle and South San Francisco. For more information, visit

CONTACT: Media Contact
Julie Rathbun
Rathbun Communications

Investor Contact
Shari Annes
Annes Associates